LYTIX BIOPHARMA Aktie

 

Oslo, Norway, 25 March 2026 – The Board of Directors of Lytix Biopharma AS (the “Company”) (Euronext Growth Oslo: LYTIX) hereby calls for the Annual General Meeting to be held at Sandakerveien 138, 0484 Oslo, Norway, on 14 April 2026 at 13:00 hours (CEST).   The agenda for the Annual General Meeting includes, among other items, approval of the Company's annual report for 2025, election of board members, approval of remuneration to the Board of Directors and the Nomination Committee, and a new board authorization to increase the share capital in connection with the Company's option...

Oslo, Norway, March 24, 2026 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, has today published its Annual Report for 2025, which was approved by the board of directors on March 23, 2026.  2025 marked a defining year for Lytix, with continued clinical progress, important strategic advancements, and a clearer pathway toward late-stage development and commercialization of its lead candidate, ruxotemitide (formerly LTX-315).  “2025 has been a defining year for Lytix Biopharma,” said Øystein Rekdal, CEO of Lytix Biopharma. “We have...

Final results from the ATLAS-IT-05 study of ruxotemitide (LTX-315) in combination with pembrolizumab to be presented at AACR 2026 Oslo, Norway, March 18, 2026: Lytix Biopharma (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that data from its Phase II ATLAS-IT-05 study evaluating ruxotemitide (LTX-315) in combination with pembrolizumab have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 20–24, 2026 in San Diego, California. The...

Oslo, Norway, 24 February 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 10 February 2026 regarding the results of a subsequent offering of new shares (the "Subsequent Offering"), raising NOK 16,306,227 in gross proceeds.   The share capital increase relating to the Subsequent Offering has been registered today with the Norwegian Register of Business Enterprises. In total, 1,811,803 shares (the "Offer Shares") have been issued through the Subsequent Offering. The Company's new share capital is NOK 7,690,000.50,...

OSLO, Norway, February 17, 2026 — Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announced the publication of a review article in the Journal of ImmunoTherapy of Cancer (JITC). The article, “Immunobiological mechanisms of action of oncolytic peptides,” was created in collaboration with the company's scientific collaborators at the Institut Gustave Roussy (France) and Fox Chase Cancer Center (USA). Bridging the Gap in Cancer Treatment While traditional therapies often struggle with "cold" tumors, or cancers that the immune...

Oslo, Norway, February 12, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”) today published its interim financial report for the second half of 2025 and released its fourth quarter 2025 presentation.   The interim report has been prepared in accordance with IAS 34 and includes financial information for the fourth quarter and the second half of 2025.   Q4 2025 highlights and developments · Positive interim clinical data from the Phase II NeoLIPA neoadjuvant melanoma study were presented by Dr Henrik Jespersen at the Nordic Melanoma Meeting in November 2025. Overall...

Oslo, Norway, February 5, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) will release its fourth quarter 2025 financial results and publish its second half 2025 financial report on Thursday, February 12, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the Q4 results and provide key insights.   Date: Thursday, February 12, 2025 Time: 10:00 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Oslo, Norway, November 18, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today releases its results for the third quarter of 2025. Post-quarter-end brought a surge of positive news for Lytix's first asset, ruxotemitide (formerly LTX-315), with two key clinical results in both neoadjuvant melanoma and basal cell carcinoma (BCC). These findings, outlined below, have prompted the company to accelerate its development plan, focusing on the fastest route to bring the groundbreaking drug to patients. Q3 2025 highlights and developments · Licensing partner Verrica Pharmaceuticals...

Oslo, Norway, November 14, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) will release its third quarter 2025 financial results on Tuesday, November 18th, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights.   Date: Tuesday, November 18th, 2025 Time: 10:00 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation.   Webcast...

Investigator-assessed pathologic complete response (pCR) observed in 44% of the first nine evaluable patients (13 total enrolled) and with no relapses reported to date. Oslo, Norway, November 11, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today announced promising interim results from an ongoing investigator-initiated Phase 2 NeoLIPA study evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab as neoadjuvant therapy in resectable melanoma. Thirteen patients have been enrolled to date, and among the first nine evaluable patients, the combination therapy has...

Oslo, Norway, November 10, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today announced that new immune response data on ruxotemitide (formerly LTX-315/VP-315) were presented on behalf of Verrica Pharmaceuticals at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland. The immunological analyses from Verrica's Phase II study in basal cell carcinoma (BCC) demonstrated strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, alongside a marked reduction in immunosuppressive T-regulatory cells in the...

Oslo, Norway, October 8, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, is pleased to announce that its license partner Verrica Pharmaceuticals Inc. will present new data from its Phase II clinical trial of VP-315 (Ruxotemitide, formerly LTX-315) for the treatment of basal cell carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5–9, 2025 in National Harbor, Maryland, USA.   VP-315 will be featured in both an oral and a poster presentation during the conference. The abstract, titled “Exploratory...

Oslo, Norway – 1 September 2025 – Lytix Biopharma AS (the “Company”) announces that the Board of Directors has approved the grant of 4,910,484 share options under the Company's long-term incentive program.   The grants cover replacement of expired options earlier this year and allocations to strengthen the incentive structure for new and existing members of the management team. The program is designed to attract, retain, and motivate highly qualified talent to drive the Company's clinical, commercial, and strategic objectives.   “Equity incentives are a key tool for aligning...

Oslo, Norway, August 28, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced its results for the second quarter and first half of 2025. The first half of the year has been a period of steady clinical progress and preparation. Lytix advanced across clinical, regulatory and organizational priorities, building a stronger foundation for the decisive period ahead.   -          Over the past years, we have validated Lytix technology across several cancer types and indications with strong results in a variety of patient populations. Our technology has...

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its second quarter 2025 financial results on Thursday, August 28th, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights.   Date: Thursday, August 28th, 2025 Time: 10:00 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation....

Oslo, Norway, May 15, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced its results for the first quarter of 2025. With strong clinical data, a clear path to Phase III, and new international leadership onboard, Lytix is entering a defining phase. The momentum seen in Q1 2025 reflects both scientific validation and growing strategic readiness, as the company sharpens its focus on late-stage development, partnerships, and commercial execution. With solid operational progress and financial discipline, Lytix is well-positioned to deliver on its ambition to...

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its first quarter 2025 financial results on Thursday, May 15th, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights. In addition, the newly elected Chair, Eric Falcand, will be introduced and he will share some of his views on the potential of Lytix's unique technology.   Date: Thursday, May 15th, 2025 Time: 11:15 AM CET   Q&A Session: We welcome your...

Oslo, Norway, April 29, 2025 – The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held on April 29, 2025. All proposed resolutions on the agenda were approved.   As part of the General Meeting, a new Board of Directors was elected in line with the recommendation from the Nomination and Compensation Committee to further reinforce the company. The newly appointed board members bring broad and complementary experience across business development, oncology, fundraising, clinical development, regulatory strategy, and financial oversight. These additions will...

Oslo, 22 April 2025 – Reference is made to the notice of the Annual General Meeting in Lytix Biopharma AS (the "Company") which will be held on Tuesday 29 April 2025 at 13.00 CEST at the Company's main office at Sandakerveien 138, 0484 Oslo, Norway.    The Company's Nomination and Compensation Committee (NCC) has submitted its formal recommendation to the General Meeting. The recommendation includes proposals for the election of board members, the election of the Chair of the Board, and the remuneration of the Board of Directors and the Nomination Committee.   The recommendation...